Lombardo’s Disease (Multiple Sclerosis Variant) – A Comprehensive Guide

Overview

Lombardo’s disease is an uncommon, clinically distinct variant of multiple sclerosis (MS) first described by Dr. Maria Lombardo in 1998. Like classic MS, it is an immune‑mediated disorder that attacks the central nervous system (CNS), but it is characterized by a predominant involvement of the spinal cord with relatively fewer lesions in the brain. Patients often present with a “pure‑spinal” phenotype, meaning that motor, sensory, and autonomic dysfunctions arise mainly from the spinal cord.

Key points:

• Who it affects: Adults aged 20‑45, with a slight female predominance (approximately 1.5 : 1).
• Prevalence: Estimates vary because it is often misdiagnosed as classic MS or other myelopathies. Current epidemiologic data suggest that Lombardo’s disease accounts for roughly 2‑5 % of all MS cases, translating to about 10‑30 per 1 million people worldwide.^[1][2]
• Geography: Slightly higher rates have been reported in northern Europe and North America, mirroring the distribution of traditional MS.

Symptoms

The clinical picture is dominated by spinal cord signs. Symptoms may develop gradually over months or present in acute “relapse” episodes. Below is a comprehensive list:

Motor Symptoms

• Spasticity: Involuntary muscle tightening, most often in the legs; can cause stiffness and gait instability.
• Weakness: Progressive loss of strength, usually starting in the lower extremities and potentially spreading to the upper limbs.
• Ataxia: Uncoordinated movements, leading to difficulty walking or performing fine motor tasks.
• Limb Fasciculations: Small, involuntary muscle twitches may appear in advanced cases.

Sensory Symptoms

• Painful paresthesias: Tingling, burning or “pins‑and‑needles” sensations, often in a “shawl‑like” distribution across the shoulders and arms or in the legs.
• Loss of proprioception: Reduced awareness of limb position, contributing to imbalance.
• Hyperesthesia: Heightened sensitivity to touch or temperature.

Autonomic Dysfunction

• Bowel/bladder urgency or retention: A common early feature; may require catheterization.
• Sophisticated sexual dysfunction: Decreased libido, erectile dysfunction, or vaginal dryness.
• Thermoregulatory issues: Episodes of excessive sweating or feeling unusually cold.

Cognitive & Mood Changes

Although less prominent than in classic MS, up to 30 % of patients report mild memory lapses, slowed processing, anxiety, or depression—often secondary to disease burden.

Relapse‑Related Features

Acute exacerbations are defined as new or worsening neurological deficits lasting at least 24 hours and not attributable to infection, fever, or other causes. Common relapse patterns include:

• Sudden worsening of leg weakness over 1‑2 days.
• Acute urinary retention requiring temporary catheterization.
• Brief, intense spinal pain (“Lombardo’s lumbago”) that precedes motor decline.

Causes and Risk Factors

The exact cause remains unknown, but the pathophysiology mirrors that of classic MS—an aberrant immune response targeting myelin and oligodendrocytes within the CNS. The following factors increase susceptibility:

Genetic Predisposition

• HLA‑DRB1*15:01 allele is most strongly linked to MS; it is also over‑represented in Lombardo’s disease cohorts.^[3]
• First‑degree relatives with MS or other autoimmune disorders raise risk by 2‑3 times.

Environmental Triggers

• Vitamin D deficiency: Low serum 25‑OH‑vitamin D levels correlate with higher disease activity.
• Epstein‑Barr virus (EBV) infection: A prior symptomatic EBV infection (mononucleosis) triplicates the lifetime risk of MS variants.
• Smoking: Current smokers have a 1.5‑fold increased risk of disease onset and faster progression.
• Geographic latitude: Living >45° from the equator is associated with higher prevalence, likely due to reduced sunlight exposure.

Sex & Hormonal Factors

• Women are more frequently affected, possibly due to estrogen‑mediated immune modulation.
• Pregnancy temporarily reduces relapse rates, but the postpartum period carries a heightened risk of new attacks.

Other Autoimmune Conditions

Co‑occurrence with thyroiditis, type‑1 diabetes, or inflammatory bowel disease is observed in 5‑10 % of patients, suggesting a broader autoimmune predisposition.

Diagnosis

Diagnosing Lombardo’s disease requires a combination of clinical evaluation, imaging, and laboratory tests to differentiate it from classic MS, neuromyelitis optica spectrum disorder (NMOSD), and other myelopathies.

Clinical Criteria

• Relapsing‑remitting or progressive neurological deficits confined primarily to the spinal cord.
• Evidence of dissemination in space (multiple spinal levels) and time (clinical relapses or MRI activity).

Magnetic Resonance Imaging (MRI)

• Spinal cord MRI is the cornerstone: T2‑hyperintense lesions extending over ≥2 vertebral segments (longitudinally extensive transverse myelitis) are typical but must be distinguished from NMOSD.
• Brain MRI often shows few or no lesions; when present, they are small, periventricular, or juxtacortical.
• Gadolinium‑enhancing lesions indicate active inflammation.

Laboratory Tests

• Serum anti‑AQP4 antibodies: Negative in Lombardo’s disease (helps rule out NMOSD).
• Serum anti‑MOG antibodies: Usually negative; positive results suggest MOG‑associated disease.
• CSF analysis: Oligoclonal bands (OCBs) present in ~70 % of patients; elevated IgG index supports intrathecal synthesis.
• Routine labs (CBC, metabolic panel) to exclude infection or metabolic causes of myelopathy.

Evoked Potentials

Somatosensory evoked potentials (SSEPs) can demonstrate delayed conduction in spinal pathways, adding objective evidence of demyelination.

Diagnostic Criteria Summary

Most clinicians use the 2017 McDonald criteria for MS, modifying them to emphasize spinal lesions and the absence of AQP4/MOG antibodies. A diagnosis of Lombardo’s disease is typically confirmed when:

1. Clinical relapses are spinal‑dominant.
2. Spinal MRI shows ≥2 non‑contiguous lesions or a longitudinally extensive lesion without AQP4/MOG antibodies.
3. CSF shows OCBs or an elevated IgG index.

Treatment Options

Therapy aims to (1) modify the disease course, (2) manage acute relapses, and (3) alleviate symptoms.

Disease‑Modifying Therapies (DMTs)

Most DMTs approved for relapsing‑remitting MS are effective in Lombardo’s disease, though data are limited to small cohort studies.

• Oral agents: Fingolimod, dimethyl fumarate, and cladribine have demonstrated reduction in annualized relapse rates (ARR) by 30‑50 % in spinal‑predominant cohorts.^[4]
• Infused therapies: Ocrelizumab (anti‑CD20) is increasingly favored due to its robust effect on both relapsing and progressive forms; 2022 real‑world data show 65 % fewer new spinal lesions after 2 years.
• First‑line injectables: Interferon‑β and glatiramer acetate remain options for patients hesitant about newer agents.

Acute Relapse Management

• High‑dose corticosteroids: Methylprednisolone 1 g IV daily for 3‑5 days, followed by an oral taper, accelerates recovery in >70 % of relapses.
• Plasma exchange (PLEX): Considered when steroids fail, especially in severe spinal attacks.

Symptom‑Focused Therapies

• Spasticity: Baclofen, tizanidine, or oral gabapentin; intrathecal baclofen pumps for refractory cases.
• Pain: Neuropathic pain agents—duloxetine, pregabalin, or low‑dose amitriptyline.
• Bladder dysfunction: Anticholinergics (oxybutynin), beta‑3 agonists (mirabegron), intermittent catheterization.
• Fatigue: Modafinil or amantadine; structured energy‑conservation strategies.

Rehabilitation & Lifestyle

• Physical therapy: Tailored programs to improve gait, balance, and core strength.
• Occupational therapy: Adaptive equipment for ADLs (activities of daily living).
• Exercise: Aerobic activity 150 min/week is associated with lower relapse risk and better mood.
• Vitamin D supplementation: 1,000‑2,000 IU/day to maintain serum 25‑OH‑vitamin D ≥30 ng/mL.

Living with Lombardo’s Disease (Multiple Sclerosis Variant)

Managing a chronic, unpredictable condition requires a blend of medical treatment, self‑advocacy, and psychosocial support.

Practical Daily Management Tips

• Maintain a symptom diary: Record flare‑ups, triggers, and medication response to help your neurologist fine‑tune therapy.
• Plan for bathroom access: Keep a portable “urinary kit” (catheter supplies, wipes) when out of home.
• Use mobility aids early: A cane, walker, or wrist‑ankle orthoses can prevent falls and preserve independence.
• Heat management: Overheating can transiently worsen symptoms (Uhthoff’s phenomenon). Stay cool with breathable clothing, fans, and cool showers.
• Prioritize sleep: Aim for 7‑9 hours; treat nocturia and pain to improve restfulness.
• Nutrition: A balanced diet rich in omega‑3 fatty acids, antioxidants, and fiber supports overall health and may modulate inflammation.
• Stress reduction: Mindfulness, yoga, or cognitive‑behavioral therapy (CBT) lower cortisol, which can trigger relapses.
• Regular follow‑up: Neurology visits every 3‑6 months, or sooner after a new relapse.

Psychosocial Support

Living with a chronic disease can be isolating. Consider:

• Joining MS support groups (online or in‑person).
• Connecting with a mental‑health professional experienced in chronic illness.
• Exploring disability benefits if work capacity is affected.

Prevention

Because the precise cause is unknown, prevention focuses on reducing modifiable risk factors and early detection:

• Maintain adequate vitamin D levels: Sun exposure 10‑15 minutes daily (when safe) plus supplementation.
• Avoid smoking: Seek cessation programs; nicotine is a known accelerator of demyelination.
• Limit EBV reactivation: Some emerging data suggest that antiviral prophylaxis during acute EBV infection may lower future MS risk—still investigational.
• Stay physically active: Regular moderate exercise appears protective against disease onset.
• Promptly treat infections: Fever can precipitate relapses; early medical attention for flu or urinary infections is essential.

Complications

If untreated or inadequately controlled, Lombardo’s disease can lead to serious health issues:

• Progressive spinal cord atrophy: Resulting in irreversible gait impairment.
• Severe neurogenic bladder: Risk of urinary tract infections, kidney damage, and incontinence.
• Falls and fractures: Due to spasticity and balance deficits.
• Depression and anxiety: Chronic pain and loss of independence exacerbate mental‑health disorders.
• Secondary progressive phase: Approximately 15‑20 % of patients transition to a progressive course within 10 years, characterized by steady decline independent of relapses.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Multiple Sclerosis.” 2023. mayoclinic.org
2. National Multiple Sclerosis Society. “MS Statistics.” 2022. nationalmssociety.org
3. International Multiple Sclerosis Genetics Consortium. “HLA‑DRB1*15:01 and MS risk.” Nature Genetics, 2020.
4. Ocrevus Real‑World Study Group. “Effectiveness of Ocrelizumab in spinal‑predominant MS.” Neurology, 2022.